Vir Biotechnology, Inc. (NASDAQ:VIR) shareholders will have a motive to smile currently, with the analysts producing substantial upgrades to future year’s statutory forecasts. Consensus estimates recommend investors could assume significantly improved statutory revenues and earnings for every share, with the analysts modelling a genuine improvement in small business efficiency. The sector could be pricing in some blue sky far too, with the share price getting 13{8ba6a1175a1c659bbdaa9a04b06717769bcea92c0fdf198d429188ebbca09471} to US$25.66 in the past 7 days. Could this improve be plenty of to generate the inventory even increased? Following the up grade, the consensus from Vir Biotechnology’s eight analysts is for revenues of US$231m in 2023, which would replicate a disturbing 90{8ba6a1175a1c659bbdaa9a04b06717769bcea92c0fdf198d429188ebbca09471} decline…